• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].

作者信息

Bruchovsky N, Goldenberg S L, Rennie P S, Gleave M

机构信息

Department of Cancer Endocrinology, Vancouver, Canada.

出版信息

Urologe A. 1995 Sep;34(5):389-92.

PMID:7483155
Abstract

Androgen suppression is the routine approach to the treatment of advanced prostate cancer. Using intermittent androgen suppression by taking the advantage of the reversible action of medical castration results in the maintenance of apoptotic potential. The experiments in the androgen-dependent androgen-dependent Shionogi carcinoma tumor model as well as clinical experience in a group of men with prostate malignancy are presented in this report. These consecutive cycles of androgen withdrawal and replacement afford an improved quality of life when the patient is off therapy. It is possible to reduce toxicity, cost of treatment and to delay tumor progression. Whether survival is affected in a beneficial or adverse way still remains to be studied.

摘要

相似文献

1
[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
Urologe A. 1995 Sep;34(5):389-92.
2
[Advanced prostatic carcinoma--which hormone therapy when?].[晚期前列腺癌——何时进行何种激素治疗?]
Urologe A. 1995 Sep;34(5):361-6.
3
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
Urologe A. 1995 Sep;34(5):382-8.
4
[Renaissance of estrogen therapy in advanced prostate carcinoma?].
Urologe A. 1995 Sep;34(5):393-7.
5
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
6
Intermittent complete androgen blockade in metastatic prostate cancer.转移性前列腺癌的间歇性完全雄激素阻断
Eur Urol. 1999;35 Suppl 1:32-6.
7
Maximal androgen blockade for advanced prostate cancer.晚期前列腺癌的最大雄激素阻断疗法。
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004.
8
[Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations].
Urologe A. 1995 Sep;34(5):374-81.
9
Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.挽救性手术联合雄激素剥夺治疗放射性复发前列腺癌:5年随访结果
J Urol. 1998 Mar;159(3):950-4; discussion 954-5.
10
[First line therapy in the treatment of metastatic prostate cancer].[转移性前列腺癌治疗中的一线治疗]
Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9.

引用本文的文献

1
Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.间歇性雄激素抑制治疗下前列腺癌患者组织多肽特异性抗原和前列腺特异性抗原的测量
Br J Cancer. 1997;75(10):1515-8. doi: 10.1038/bjc.1997.259.
2
The antiandrogen withdrawal syndrome.抗雄激素撤药综合征。
Urol Res. 1997;25 Suppl 2:S67-71. doi: 10.1007/BF00941991.